Identifying predictors of treatment outcome for nicotine use disorders (NUDs) may help improve efficacy of established treatments, like varenicline. Brain reactivity to drug stimuli predicts relapse risk in nicotine and other substance use disorders in some studies. Activity in the default mode network (DMN) is affected by drug cues and other palatable cues, but its clinical significance is unclear. In this study, 143 individuals with NUD (male n = 91, ages 18-55 years) received a functional magnetic resonance imaging scan during a visual cue task during which they were presented with a series of smoking-related or food-related video clips prior to randomization to treatment with varenicline (n = 80) or placebo. Group independent components analysis was utilized to isolate the DMN, and temporal sorting was used to calculate the difference between the DMN blood-oxygen-level dependent signal during smoke cues and that during food cues for each individual. Food cues were associated with greater deactivation compared with smoke cues in the DMN. In correcting for baseline smoking and other clinical variables, which have been shown to be related to treatment outcome in previous work, a less positive Smoke À Food difference score predicted greater smoking at 6 and 12 weeks when both treatment groups were combined (P = 0.005, β = À0.766). An exploratory analysis of executive control and salience networks demonstrated that a more positive Smoke À Food difference score for executive control network predicted a more robust response to varenicline relative to placebo. These findings provide further support to theories that brain reactivity to palatable cues, and in particular in DMN, may have a direct clinical relevance in NUD.
INTRODUCTION
There are several efficacious pharmacotherapeutic agents for the treatment of nicotine use disorder (NUD), including bupropion, varenicline and nicotine replacement therapies (NRT) (Hartmann-Boyce et al. 2014) . In particular, varenicline, a partial agonist at the nicotinic acetylcholine receptor (Rollema et al. 2007 ) is associated with higher quit rates than NRT and bupropion, with no evidence of a significant increase in serious adverse events (Hartmann-Boyce et al. 2014) . However, more than 80 percent of individuals entering treatment, even when treated with varenicline, end up relapsing by 6 months (Richmond & Kehoe 2007; Westergaard et al. 2015) .
Searching for individual characteristics to predict outcomes to particular treatments for substance use disorders (SUD) has been a focus of research for over three decades with the idea that by matching treatments to particular subgroups more likely to benefit, treatment efficacy can be enhanced. In alcohol use disorders (AUD), some progress has been made for some of the pharmacotherapeutic agents (Mann et al. 2014; C.E. Wilcox & Bogenschutz 2013) . In NUD, the majority of the studies that have tried have not been able to identify subgroups more likely to respond to bupropion, NRT (Niaura et al. 1994; Aubin et al. 2004; Brody et al. 2014) or varenicline (McClure et al. 2010; Perkins et al. 2010) . For varenicline, a few exceptions to this exist. Studies have identified associations between activation in brain areas related to attentiveness and memory while resisting an urge to smoke (Hartwell et al. 2013) , the presence of certain nicotinic acetylcholine receptor subunit genes (D. P. King et al. 2012) and nicotine metabolism rates (Lerman et al. 2015) and treatment outcome to varenicline. To date, no studies have identified whether brain activation during smoking cues predicts treatment outcome on varenicline, however.
Predicting outcomes in general during treatment is also important; clinically, it can help inform decisions about treatment intensity such as those regarding high versus low doses or combined treatments versus single treatments. For overall outcome prediction in NUD, results have been mixed but indicate that absence of neuropsychiatric disorder and lower psychiatric symptom severity (Ferguson et al. 2003) , older age, longer duration of previous quit attempts, lower dependence severity, adherence to pharmacotherapy, absence of smoking-related disease, male gender, low level of current alcohol problems, living as a couple (Ferguson et al. 2003; Aubin et al. 2004; Wee et al. 2011; Iliceto et al. 2013 ) and lower impulsivity (Sheffer et al. 2012 ) predict better treatment outcomes. Functional brain imaging may have an advantage over self-report measures because of its sensitivity and because of the mechanistic insights it provides. Incentive salience, referring to the wanting or desire response that the brain has to a drug stimulus [as measured primarily in humans during functional magnetic resonance imaging (fMRI) by brain cue reactivity], is one of the three primary dimensions for the proposed Addictions Neuroclinical Assessment framework, highlighting its importance as a core functional domain underlying SUD pathophysiology (Kwako et al. 2015) . In particular, there is a growing literature on the potential importance of drug cue reactivity in predicting treatment response in a variety of SUD (Janes et al. 2010; Mann et al. 2014; Versace et al. 2014; Courtney et al. 2016) , and it also has been shown to predict response to particular treatments in AUD (Mann et al. 2014) .
The default mode network (DMN) is a set of brain regions that tends to demonstrate decreased activation during attentionally demanding and cognitively challenging tasks and is anticorrelated with executive control networks (ECNs) mediating goal-oriented behavior (Fox et al. 2005; Anticevic et al. 2012) . DMN deactivation likely plays an important role in successful goal-oriented cognition and behavior (Anticevic et al. 2012) , which could hold relevance for drug seeking, on the one hand, or maintaining online a decision to remain abstinent, on the other. Deactivation in regions of the DMN (rostral anterior cingulate cortex and posterior cingulate cortex) has been observed in response to nicotine, cocaine and food cues (Claus et al. 2013; Tomasi et al. 2015; C. E. Wilcox et al. 2011) in some studies, but in others, activation has been observed in these areas (Engelmann et al. 2012) . Therefore, the findings regarding the effects of drug cues on the DMN and regions encompassing the DMN are mixed. The significance of the brain's response to these cues in driving relapse during SUD treatment is still unknown.
Our primary aim in this study was to investigate the degree to which DMN deactivation to smoking cues relative to food cues would predict treatment response to varenicline in particular and overall treatment response in treatment-seeking individuals with NUD enrolled in a clinical trial of varenicline versus placebo. As greater DMN deactivation to food cues compared with smoke cues was measured in a non-treatment-seeking sample using the same task (Claus et al. 2013) , we hypothesized that our sample would demonstrate a similar effect. Furthermore, we explored the degree to which deactivation to smoke cue, food cue and the difference between them would predict better clinical outcomes, controlling for the predictive effects of self-report clinical measures, which have shown to predict outcome in previous work. Finally, we explored activation in ECN and salience network (SN) and their associations with outcomes, given the fact that these networks are often engaged by drug cues and anticorrelated with DMN (Fox et al. 2005; Anticevic et al. 2012; Lerman et al. 2014) .
PATIENTS AND METHODS

Subjects
Subjects were treatment-seeking cigarette smokers between the ages of 18 and 55 years recruited and enrolled in a randomized, double-blind, placebo-controlled trial of varenicline, which was designed to identify biomarkers of effectiveness [manuscript summarizing clinical results, under review (Littlewood et al. submitted) ]. Individuals were required to smoke at least 10 cigarettes per day and to have not previously taken varenicline. Participants were excluded for current pregnancy/nursing, use of illicit drugs (excluding marijuana) in the past 60 days (confirmed by urine toxicology screen), serious health concerns (cardiovascular disease, uncontrolled hypertension, hepatic or renal disease, and diabetes) or meeting DSM-IV criteria for psychotic, bipolar or major depressive disorder in the past year. Two hundred five individuals were randomized using an urn randomization technique and treated for 12 weeks. Of these, 143 underwent a cue-exposure task during fMRI prior to medication initiation (male n = 91; varenicline n = 80; mean age 34.05 years; standard deviation, 10.16), and their data were used for the analyses that follow; individuals who chose not to have an MRI or had exclusions for MRI were still enrolled in the clinical trial.
Clinical trial design
Consistent with previous trials (Gonzales et al. 2006) , patients were titrated to 1 mg twice daily, as follows: days 1-3, 0.5 mg per day; days 4-7, 0.5 mg twice per day; and after day 7, 1 mg twice per day. All participants received a 30-minute baseline motivational enhancement session during which a target quit date was set for day 8, and brief (10-minute) counseling visits with their assigned therapist at each assessment (2, 6 and 12 weeks) (Littlewood et al. submitted) .
Clinical assessments
A battery of assessments were obtained at screen, baseline, and 2, 6 and 12 weeks. Only measures relevant to this study are summarized subsequently; a full description of the clinical assessment measures is provided in the clinical outcomes paper (Littlewood et al. submitted) . Nicotine dependence was characterized using the Fagerstrom Test for Nicotine Dependence. Nicotine withdrawal was assessed using the Wisconsin Smoking Withdrawal Scale (WSWS) and craving with the Questionnaire of Smoking Urges and were obtained 15-30 minutes before each MRI scan. A separate subscale of the WSWS [WSWS(food)], which included only the questions that were related to desire for food, was calculated (see Supporting Information for details). Number of hours since the last cigarette smoked was also obtained from the participant at the time of each MRI scan; participants were asked to be abstinent for 2 hours prior to the scan visit, and there were only eight participants who did not report being abstinent 2 hours prior to the scan. Additional measures included the Beck Anxiety Inventory, the Beck Depression Inventory, the Barratt Impulsiveness Questionnaire (BIQ) and the alcohol use disorder identification test (references for self-report measures listed in Supporting Information). All participants were also asked at the screen visit about the number of prior serious quit attempts they had made in their lives during which they remained abstinent from cigarettes for 12 hours or more. Carbon monoxide (CO) levels were obtained at all visits, which were used to validate secondary abstinence-based outcome variables (Tables 6, 7 and S1-3).
The time-line follow-back procedure (reference in Supporting Information) was used to record tobacco product, alcohol and drug use in the 60 days prior to the screen and during the interim period between each follow-up assessment. The baseline smoking rate was calculated as the total number of cigarettes smoked (NumCig) during the 60 days before the screen visit. Low rates of complete abstinence in the placebo group (n = 4 at 6 weeks for 7-day point prevalence) rendered logistic regression problematic as a method of analysis to examine the interaction term [component beta × treatment group (RxGrp)], given small sample bias (G. King & Zeng 2001) . We therefore utilized continuous outcome variables as our primary outcome: NumCig during the previous 28 days for the 6-week smoking outcome and NumCig during the previous 30 days for the 12-week smoking outcome. Although abstinence is more commonly used as a measure of success in smoking cessation trials, smoking reduction is still a meaningful outcome that predicts later cessation (Begh et al. 2015) . For dropouts, missing outcomes data were imputed to an adjusted screen visit value [e.g. (NumCig at screen visit) * 28/ 60 = NumCig at 6 weeks] (n = 27/143 for week 6 and n = 44/143 for week 12) for our primary analysis. Imputing to baseline (assuming missing subjects revert to baseline smoking levels) is a common approach for smoking cessation clinical trials (Higgins et al. 2008; Ebbert et al. 2015) even when rates of dropout approach ours. We also present results for an analysis performed on individuals with complete data.
Cue-exposure task
The cue-exposure task is identical to the task for which results in a different sample of non-treatment-seeking smokers is published (Claus et al. 2013 ) (details in Supporting Information). In brief, the task consisted of two 6-minute runs with pseudorandom presentations of seven different smoking-related videos and seven different food-related videos per run, ranging in length from 7 to 14 seconds, and depicting images of preparation of the stimulus for ingestion and the act of ingestion itself.
MRI acquisition and preprocessing
All scans were acquired on a Siemens 3T Trio scanner located at the Mind Research Network (Albuquerque, NM, USA) using procedures previously described (Claus et al. 2013) . Data were preprocessed using SPM5 software (http://fil.ion.ucl.ac.uk/spm/software/spm5) using standard methods (details in Supporting Information).
ICA methods
Infomax group spatial ICA (Calhoun et al. 2001) was conducted to decompose the data into components using GIFT software (http://mialab.mrn.org/software/gift). Thirty-five components for the previous data reduction step and 30 components for the final data reduction step were chosen [typical for low order models (Ma et al. 2011) ]. To estimate subject-specific spatial maps and time courses, the GICA back-reconstruction method was used (Calhoun et al. 2001; Erhardt et al. 2011) . ICA was repeated 10 times using ICASSO (http://research.ics.aalto.fi/ica/icasso/), and the 'best run' was selected to mitigate variation due to the stochastic estimation process (Ma et al. 2011) . The resulting component runs were also clustered to estimate the reliability of the decomposition. Robustness and reliability of components were well validated by the ICASSO results showing compact and independent/non-overlapping clusters. Following ICA, time series were filtered using a low-pass filter of >0.15 Hz and detrending to remove low-frequency noise (high-pass filter). In correcting for head motion, time series were then despiked, and motion was regressed out on a per-subject basis using the six motion parameters. In addition, mean root mean squared translational (rmsTrans) and rotational (rmsRot) framewise displacement were calculated for each subject (Jenkinson 2003) .
Component selection
Spatial maps were reconstructed and converted to Z values for each of the subjects. A standardized DMN mask [rDMN_ICA_REST*.nii; http://mialab.mrn.org/data (Rachakonda et al. 2007; Franco et al. 2009 )] was used to select the DMN component from the 30 estimated components using the spatial sort function in GIFT; we selected the component that was most strongly associated with our a priori template (R 2 = 0.42) (Fig. 1a ). This method was chosen so that our analyses could be systematically replicated in other samples. Compared with the rest, previous works have shown that tasks may also modulate some of the spatial maps (Calhoun et al. 2008) , but the change is not large, so the use of a rest DMN template is reasonable. The ECN [right(R) and left(L)] and SN were identified visually by anatomical overlap with previous studies of these networks in smokers (Lerman et al. 2014) .
Temporal sort and development of the component predictor variables
For each component, we determined its task relatedness using temporal sorting in GIFT, which utilizes the time course of the component as the dependent variable, and variables from the design matrix of the task as independent variables. Food cues, smoking cues and a constant were modeled, which produced betas associated with each of the regressors. These betas are similar to those one would see from a typical voxelwise GLM analysis such as those performed in previous work with the same task (Claus et al. 2013) , except that the betas represent the degree to which the condition of interest is associated with increases/decreases in network activity rather than individual voxel activity. Similar analyses were performed for the ECN, SN and bilateral cuneus (negative control).
Betas associated with smoke cues (Smoke) and food cues (Food) were extracted for each individual subject, and the difference between Smoke and Food was calculated (Smoke À Food). t-Tests were computed on the beta values corresponding to Food and Smoke to establish whether or not there was a difference between the networks' response to the two cue types. 
Clinical outcome prediction
Our outcome variables (NumCig 6 and 12 weeks) were count variables that appeared to have a Poisson distribution but did not meet the assumption required for a Poisson distribution (mean equaling variance), so we chose a negative binomial with log link model to predict clinical outcomes in SPSS. This is the model of choice when a dependent variable has many zero values, and it assumes over-dispersion (Alison 2012) . In order to test a repeated measures outcome composed of correlated variables (smoking at 6 and 12 weeks), we used generalized estimating equations with a robust covariance estimation method and assigned time as a within-subjects variable, and smoking as our outcome variable, which outputs a single test for the relationship between predictor and smoking outcome incorporating both 6-and 12-week smoking outcomes. Maximum likelihood estimation was used to estimate the negative binomial dispersion parameters, and correlation matrix representing within-subjects dependencies was assigned as AR (1). P values associated with the Wald χ 2 were used to test significance of predictors.
Given previous work highlighting the importance of comorbid psychiatric symptoms (Ferguson et al. 2003) , age, dependence severity, longer duration of prior quit attempts, gender, presence or absence of current alcohol problems (Ferguson et al. 2003; Aubin et al. 2004; Wee et al. 2011; Iliceto et al. 2013 ) and impulsiveness (Sheffer et al. 2012) in treatment success, we chose to include the following clinical predictors in our outcome prediction model: Fagerstrom Test for Nicotine Dependence, age, gender, Beck Depression Inventory, Beck Anxiety Inventory, BIQ, number of serious previous quit attempts and alcohol use disorder identification test. NumCig at screen (over the previous 60 days), RxGrp, baseline demographic and clinical predictors associated with outcome in previous work, the neuroimaging predictor (Smoke À Food) and an interaction term (Smoke À Food/Smoke À Food × RxGrp) were also entered as predictors, and NumCig at 6 and 12 weeks (over the previous 28 and 30 days, respectively) as the predicted outcomes. When the interaction term was not significant, we reran the model without it.
In addition, we also ran the same model that we ran using Smoke À Food but using Smoke or Food alone as the neuroimaging predictor variable. Additionally, we also ran the same models in the subset of individuals with complete data only. Finally, we reran the models with fewer (only the essential) covariates. Finally, we used independent samples t-tests to compare the values for Smoke À Food, Smoke and Food between abstinent and non-abstinent individuals at 6 and 12 weeks respectively, results for which are summarized in Table 6 , 7 and S1-3. Table 1 presents the baseline demographic characteristics of individuals included in these analyses by medication group and shows no significant differences between groups at baseline. Correlations (Spearman's ρ) between demographic and clinical variables and between these potential predictors and outcome were calculated and presented in Table 2 . Although head motion (framewise 4.4 (5.6) 3.6 (3.8) Beck Depression Inventory total score (SD) 2.6 (4.2) 3.6 (4.6) Barratt Impulsiveness Questionnaire 60.7 (11.1) 63.6 (11.4) Wisconsin Smoking Withdrawal Scale score-before scan (SD) 11.2 (3.9) 11.9 (3. À0.14 À0.22** 0.82** 12wk = total number of cigarettes smoked during prior 30 days at the 12-week follow-up visit; 6wk = total number of cigarettes smoked during prior 28 days at the 6-week follow-up visit; Aud = alcohol use disorder identification test total score; BAI = Beck Anxiety Inventory total score; BDI = Beck Depression Inventory total score; BIQ = Barratt Impulsiveness Questionnaire; F = beta for degree of association of default mode network component with food cues; FTN = Fagerstrom Test for Nicotine Dependence; Gen = gender (male = 1, female = 2); Hrs = hours since last cigarette was smoked prior to the magnetic resonance imaging scan; Quit = number of times an attempt to quit smoking made where participant stayed off cigarettes for >12 hrs; rmsR = root mean square translational framewise displacement (latter 2 variables approximate head motion during the cue task); rmsT = root mean square translational framewise displacement; RxGrp = medication condition (varenicline = 1, placebo = 0); S = beta for degree of association of default mode network component with smoke cues; Scr = total number of cigarettes smoked during prior 60 days at the screen visit; S-F = beta for degree of association of default mode network component with smoke cues minus for food cues; WS = Wisconsin Smoking Withdrawal Scale score-pre-magnetic resonance imaging scan; WSf = sum of food-related questions only on Wisconsin Smoking Withdrawal Scale.^Significant at P < 0.1. *Significant at P < 0.05. **Significant at P < 0.01. displacement as measured by rmsRot and rmsTrans) was not correlated with Smoke, Food or Smoke À Food (Ps > 0.1), it was negatively correlated with NumCig at 12 weeks (Table 2) . Because rmsRot and rmsTrans were highly correlated with one another (ρ = 0.817, P < 0.001), to avoid problems of multi-collinearity (Tabachnick & Fidell 1996) , we chose to include only rmsRot as a covariate in all outcomes analyses because it was more strongly correlated with 12-week NumCig (ρ = À0.218, P = 0.009) than rmsTrans. Both WSWS and WSWS(food) were weakly correlated with the DMN Food (ρ = 0.141, P = 0.094) and Smoke À Food (ρ = À0.154, P = 0.068) betas, respectively, and so both were included as covariates in the analyses. Although Questionnaire of Smoking Urges was not correlated with DMN Smoke À Food or NumCig at 6 weeks, it was weakly correlated with Smoke (ρ = 0.144 P = 0.087), Food (ρ = 0.151, P = 0.072) and NumCig at 12 weeks (ρ = 0.168, P = 0.045) and so was also used as a covariate in all analyses. Hours since last smoked at the time of the scan was correlated neither with the neuroimaging predictor of interest (Smoke À Food) nor with NumCig at 6 or 12 weeks (Table 2 ) and was not used as a covariate. CO levels were obtained, and not used in the analyses, but were highly correlated with NumCig at 6 (P = 0.000, ρ = 0.732) and 12 weeks (ρ = 0.606, P < 0.001). Of those with a CO > 10 ppm, only two subjects reported no cigarettes smoked at 6 weeks and only three subjects at 12 weeks. The only clinical variable that was significantly correlated with Smoke À Food was the BIQ (ρ = À0.20, P < 0.05). The DMN component was strongly negatively associated with onset of Food and weakly negatively associated with onset of Smoke (Table 3; Fig. 1b) . A paired t-test (n = 143) demonstrated significant differences between betas associated with Smoke and those associated with Food. For our exploratory components, paired t-tests demonstrated significant differences between the betas associated with Smoke versus Food for R ECN and L ECN but not for SN (Table 3) . Correlations between the DMN and exploratory components (Table 4) For Smoke À Food for the DMN component, the interaction term (Smoke À Food × RxGrp) was not significant (P = 0.673), and the model was rerun without it. There was a significant overall effect (P = 0.005, β = À0.766, exponential beta [Exp(B)] = 0.47) of the DMN component for Smoke À Food on smoking outcome Fig.2 , such that a smaller beta weight difference predicted less reduction in smoking at the follow-up appointment (Table 5 ). These findings indicated that the more the profile of the DMN component during the smoke cues approached that of the food cues, the worse the treatment outcome. Additionally, although there were no significant interaction terms when Food and Smoke models (Smoke × RxGrp P = 0.796; Food × RxGrp P = 0.809) were run separately, Food (P = 0.006, β = 0.678, Exp(B) = 1.97) but not Smoke (P = 0.720, β = À0.102, Exp(B) = 0.72) predicted smoking outcome, indicating that a smaller degree DMN = default mode network; ECN = executive control network; F = beta for degree of association of component with food cues; L = left; R = right; S = beta for degree of association of component with smoke cues; S-F = beta for degree of association of component with smoke cues minus for food cues; SN = salience network.^Significant at P < 0.1. *Significant at P < 0.05. **Significant at P < 0.01.
RESULTS
of DMN deactivation during food cues predicted a worse treatment outcome (Table 5) . From the standpoint of clinical variables, the strongest outcome predictors in all three models were the number of cigarettes the participant reported in the 60 days prior to the screen visit, the medication group assignment and the number of reported previous serious quit attempts.
Repeating the analyses with all of the same covariates on individuals with complete data only (not imputing to baseline smoking) showed no significant interaction terms (Ps > 0.01), a significant effect of Smoke À Food (P = 0.049, β = À0.715, Exp(B) = 0.489) but no effects of Smoke (P = 0.296, β = À0.469, Exp(B) = 0.626) or Food (P = 0.427, β = 0.304, Exp(B) = 1.355) on smoking outcome. These and results for abstinence-based outcomes (Table 6 , 7 and S1-3) support the particular importance of the Smoke À Food contrast over that of the individual cue types (Smoke alone, Food alone) for predicting treatment outcome. Finally, to confirm that over-fitting was not the driving results, we reran the outcome prediction analyses dropping variables demonstrating no relationship with outcome, which showed similar results (Table S4) .
For the exploratory components, we ran the same generalized estimating equation models using a smaller subset of covariates to avoid over-fitting (see Supporting Information for details) and observed significant (or trending towards significant) interaction terms for R ECN for the full (imputed) sample for Smoke (P = 0.048) and Smoke À Food (P = 0.059), for L ECN for individuals with complete data only (non-imputed) sample for Smoke À Food (P = 0.045) and for SN for Food for individuals with complete data only (P = 0.009) and for SN for individuals with complete data only for SmokeFood (P = 0.067). There were no additional significant interaction terms or, when models were rerun without the interaction terms, overall significant relationships between Food, Smoke and Smoke À Food betas associated with ECN, SN or cuneus (negative control) and outcome. The interactions were explored further (Table 8) in two ways: (1) we did a median split on the betas associated with the cue of interest and then ran the analyses and looked for differences in the RxGrp effect and (2) we split groups into varenicline and placebo groups and looked for differences in the ability of the betas to predict outcome. These analyses indicated that varenicline worked best (relative to placebo) in individuals who had more positive values for Smoke and Smoke À Food in R ECN, who had more positive values for Smoke À Food in L ECN, and in individuals who had greater activation of ecause the interaction terms (Smoke À Food × RxGrp, Smoke × RxGrp, Food × RxGrp) were not significant or trending towards significant, results without the interaction terms are presented. Gender (male = 1, female = 2). AUDIT = alcohol use disorder identification test total score; BAI = Beck Anxiety Inventory total score; BDI = Beck Depression Inventory total score; BIQ = Barratt Impulsiveness Questionnaire total score; DMN = default mode network; Exp(B) = exponential beta; Food = beta for degree of association of DMN component with food cues; FTND = Fagerstrom Test for Nicotine Dependence; QSU = Questionnaire of Smoking Urges; Quit = Number Serious Quit Attempts (>12 hours' abstinent); rmsRot = root mean square translational framewise displacement (head motion at time of magnetic resonance imaging scan); RxGrp = Medication Condition (varenicline = 1, placebo = 0); Scr = number of cigarettes smoked during prior 60 days at screen; SmokeFood = beta for degree of association of DMN component with smoke cues minus for food cues; Smoke = beta for degree of association of DMN component with smoke cues; WSW = Wisconsin Smoking Withdrawal Scale score pre-magnetic resonance imaging scan; WSWFood = sum of food-related questions only on Wisconsin Smoking Withdrawal Scale.^P < 0.1. *Significant at P < 0.05. **Significant at P < 0.01. 
DISCUSSION
In summary, DMN response to smoke relative to food cues was associated with treatment outcome, controlling for several clinical variables associated with treatment outcome in previous work. Specifically, a lower value for Smoke À Food during the task predicted a greater likelihood of poor outcome during treatment, indicating that the more the deactivation of the DMN to the smoke cues approached that associated with the food cues, the worse outcome the individual was likely to have. DMN is active in self-referential processing and rumination and deactivated during tasks that are attention grabbing and require executive control (Fox et al. 2005) . We had expected that there would be greater deactivation in DMN to food cues compared with smoke cues, on the basis of previous work (Claus et al. 2013; Tomasi et al. 2015 ). An explanation for this somewhat counterintuitive but replicating finding is that, even in individuals with SUD, food cues are often still more palatable than drug cues (as demonstrated in previous work in AUD assessing palatability of alcohol versus food cues) (Pronk et al. 2015) . The degree of deactivation to food cues could be understood to represent the general capacity of the DMN to deactivate to a palatable cue and may serve as a baseline that represents the maximum degree to which the cue can capture an individual's attention. Our outcome prediction findings could therefore indicate that individuals for whom the smoking cue has a greater ability to capture attention relative to the overall capacity of the DMN to deactivate (as represented by the response to food cue) are more vulnerable to relapse during treatment.
Another additional surprising finding was that the DMN's response to food cue was independently able to predict treatment outcome, such that a lower degree of DMN deactivation during food cues predicted a worse treatment outcome. Granted, this effect was not present in the supporting analyses that involved using only the available data, or the analyses comparing neuroimaging variable values between abstinent and non-abstinent individuals (Table 6 , 7 and S1-3), and the effect of food cues in the primary analyses was smaller than that observed for the difference score. However, these findings could indicate that general DMN pathology is driving some of the Smoke À Food results, and that lower deactivation to food cue may be a biomarker of muted response to natural rewards (Tomasi et al. 2015) . Relatedly, individuals with more severe levels of dependence may have muted responses to food cues owing to effects of chronic Table 6 Means for neuroimaging predictor variables by abstinent versus non-abstinent subgroups for the 7 days prior to week 6 (CO confirmed), and comparisons between abstinent and non-abstinent groups (independent samples t-tests), assuming all dropouts were non-abstinent.
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S mean (SD) F mean (SD) n CO confirmed = anyone with a CO > 10 ppm at the 6-week visit were deemed non-abstinent regardless of self-report; F = beta for degree of association of default mode network component with food cues; PP = point prevalence; S = beta for degree of association of default mode network component with smoke cues; SD = standard deviation; S-F = beta for degree of association of default mode network component with smoke cues minus for food cues. Table 7 Means for neuroimaging predictor variables by abstinent versus non-abstinent subgroups for the 30 days prior to week 12 (CO confirmed), and comparisons between abstinent and non-abstinent (independent samples t-tests), assuming all dropouts were non-abstinent. CO confirmed = anyone with a CO > 10 ppm at the 12-week visit were deemed non-abstinent regardless of self-report; F = beta for degree of association of default mode network component with food cues; PP = point prevalence; S = beta for degree of association of default mode network component with smoke cues; SD = standard deviation; S-F = beta for degree of association of default mode network component with smoke cues minus for food cues.
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smoking on neuropeptide levels regulating appetite (Chen et al. 2008) . The predictive effects of DMN on smoking outcome were observed after correcting for the effects of other clinical covariates that have been previously observed to predict outcomes during smoking cessation treatment. In this study, baseline number of cigarettes smoked, number of previous quit attempts and, more weakly, self- Other predictors were included in these models (specifics in Supporting Information), but results are not reported here for simplicity. ECN = executive control network; Exp(B) = exponential beta; Food = beta for degree of association of component with food cues; L = left; R = right; RxGrp = medication condition (varenicline = 1, placebo = 0); Smoke À Food = beta for degree of association of component with smoke cues minus for food cues; Smoke = beta for degree of association of component with smoke cues; SN = salience network.^P < 0.1. *Significant at P < 0.05. **Significant at P < 0.01.
reported dependence severity were predictors of outcome (in addition to medication group assignment, as expected), but the other clinical variables were not. These findings highlight the potential importance of using brain activation during drug cues to predict treatment outcomes as it may turn out to be a more sensitive or reliable marker of future clinical behavior. Indeed, in other work in NUD, greater insula activation to smoking cues was significantly predictive of worse outcome, observed with only 21 subjects (η p 2 = 0.27; large effect) (Janes et al. 2010) , and smokers who showed lower pre-quit levels of brain reactivity to pleasant stimuli than to cigaretterelated cues were less likely to be abstinent 6 months after their quit attempt, observed with only 55 subjects (odds ratio of 6.34 at 24 weeks; medium to large effect) (Versace et al. 2014) .
The results from the exploratory analyses of ECN and SN were notable. For one, in line with our working model that food cues were more engaging than smoke cues, food cues were associated with greater (positive) engagement of both ECN (significant) and SN (non-significant) compared with smoke cues. Second, DMN was negatively correlated with SN, in line with previous work (Lerman et al. 2014) , but, surprisingly, it was not negatively correlated with ECN. In the presence of appetitive cues, the relationships between ECN and DMN may be different than they are during cognitive tasks or at rest. Most importantly perhaps, there were significant interaction terms (Smoke À Food/Smoke/Food × RxGrp) when these networks were used as predictors. Exploring these interactions further indicated that some of these markers (more positive values in R ECN to Smoke À Food and to Smoke, more positive values in L ECN to Smoke À Food and greater activation in SN to Food) might prove useful in treatment matching as they identify individuals more likely to respond to treatment with varenicline. Furthermore, more positive values of Smoke À Food for R ECN was associated with greater improvement in individuals on varenicline but not placebo. Previous work has shown that varenicline is associated with decreased activation to smoking cues in regions of the R ECN (Franklin et al. 2011) . In combination with our data, this might indicate that varenicline is working in this region in individuals with greater activation to Smoke and Smoke À Food by decreasing smoking cue-induced signal.
That the food cues were associated with greater deactivation in DMN than the smoke cues (in fact, the smoke cues alone resulted in almost no mean DMN deactivation) could indicate that food cues were more appetitive; unfortunately, one limitation to our study is that we did not obtain ratings of palatability. However, even if this is true, this was not an especially striking limitation, given that the difference between these two cues was still able to predict clinical outcome. Although individuals with SUD are generally conceptualized to have increased sensitivity to drug rewards but lower sensitivity to natural rewards such as food (Koob & Volkow 2009; Volkow et al. 2010) , this is not always observed in NUD; other work has demonstrated that some individuals with NUD responded more to smoking cues relative to other pleasurable cues, and others less, and that these categories predicted smoking outcomes during NUD treatment (Versace et al. 2014) . Both these results (Versace et al. 2014 ) and our findings demonstrate that it is the relative strength of these cues that matters clinically in NUD. Furthermore, one could raise concerns about the validity of using food cues as a baseline, especially because an individual's hunger levels could affect the brain's response (Thomas et al. 2015) . For this reason, we included a measure of food craving [WSWS(food)] as a covariate in all relevant analyses, to control for this. Finally, in some cases, results differed between the full sample (outcomes imputed to baseline) and the smaller sample with complete data (DMN Food; Table 8 ); when results did not replicate in both samples, we did not highlight them in the discussion. These differences may have been driven by differences between the populations (details in Supporting Information).
In summary, these findings indicating that DMN deactivation to smoke cues relative to food cues robustly predicted clinical outcome are novel and important. Notably, this is one of the first works in any SUD to directly investigate the pattern of DMN activity during the processing of palatable cues and to investigate the relationship between DMN deactivation to drug cue in relation to food cue as a marker of relapse vulnerability. Although brain activation to nicotine and other drug cues have been studied and documented and its clinical importance established in a variety of clinical populations (Janes et al. 2010; Franklin et al. 2011; Mann et al. 2014; Versace et al. 2014; Kwako et al. 2015; Courtney et al. 2016) , very little work has focused on the effects of drug and other reward cues on DMN activity and its clinical relevance. Future work should attempt to replicate these findings in other NUD treatment samples, as well as in other SUD, to identify whether or not this is a reliable method to predict overall treatment outcome and/or predict response to particular treatments.
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Additional Supporting Information may be found online in the supporting information tab for this article. Figure S1 . This figure shows the exploratory (R ECN = right executive control network, L ECN = left executive control network, SN = salience network, Cuneus) components with each sagittal, coronal, and axial slice marked with a number representing the MNI x,y,z coordinate respectively. Red indicates voxels which are more positively associated with the component (positive Z scores), and blue indicates voxels which are more negatively associated with this component (negative Z scores) Table S1 . Means for neuroimaging predictor variables by abstinent versus non-abstinent subgroups for the 7 days prior to week 6 (CO confirmed), and comparisons between abstinent and non-abstinent (independent samples t-tests), including only participants with complete data Table S2 . Means for neuroimaging predictor variables by abstinent versus non-abstinent subgroups for the 30 days prior to week 12 (CO confirmed), and comparisons between abstinent and non-abstinent (independent samples t-tests), including only participants with complete data Table S3 . Means for neuroimaging predictor variables by membership in one of the defined six subgroups based on the results for the 30 days prior to week 12 (CO confirmed) variable Table S4 . Outcome Prediction Results Using Generalized Estimating Equations for DMN: Simplified
